Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
viagenpumatucel-L + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Heat Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
Viagenpumatucel-L + pembrolizumab is a combination therapy under investigation for the treatment of advanced non-small cell lung cancer (NSCLC). **Viagenpumatucel-L (HS-110)** is an allogeneic therapeutic cancer vaccine developed to stimulate the immune system against multiple tumor antigens found in NSCLC, utilizing a cell-based technology expressing gp96-Ig to activate CD8+ cytotoxic T-cells through cross-presentation to MHC I[3][5]. **Pembrolizumab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to release the brakes on the immune response and enhance anti-tumor activity. Clinical studies have evaluated this combination therapy to determine if checkpoint inhibition via pembrolizumab may be potentiated by antigen-specific immune activation from viagenpumatucel-L, especially in PD-L1-low tumors[1][5].
- Brand names
- KEYTRUDA
- Other names
- viagenpumatucel-Lpembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TAA/gp96-Ig (Tumor-associated antigens presented via gp96-Ig)
Beyond the preview
Go deeper on viagenpumatucel-L + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on viagenpumatucel-L + pembrolizumab.